A Phase 1 Study of SGN-CD48A in Patients With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase 1 Study of SGN-CD48A in Patients With Relapsed or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2018

At a glance

  • Drugs SGN-CD48A (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 07 Mar 2018 According to a Seattle Genetics media release, the first patient has been dosed in this trial.
    • 08 Feb 2018 Planned End Date changed from 1 Jun 2021 to 1 Jul 2021.
    • 08 Feb 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top